How effective is the combination of everolimus and lenvatinib?

The combination of everolimus and lenvatinib has shown significant efficacy in the treatment of advanced renal cancer. The combined use of these two drugs can double inhibit the different growth pathways of renal cancer cells, thereby improving the therapeutic effect.

Everolimus is an mTOR inhibitor that mainly prevents the growth and proliferation of cancer cells by inhibiting the mTOR signaling pathway. The mTOR signaling pathway is abnormally active in a variety of cancers, including kidney cancer. By inhibiting this pathway, everolimus can slow tumor growth and even cause tumors to shrink.

Lenvatinib is a multi-target tyrosine kinase inhibitor that can inhibit multiple targets related to tumor growth and angiogenesis, includingVEGFR, FGFR, etc. It inhibits tumor angiogenesis and cancer cell proliferation by blocking signaling at these targets. In the treatment of kidney cancer, lenvatinib can significantly reduce the blood supply to tumors and further inhibit tumor growth and spread.

When everolimus and lenvatinib are combined, the two drugs work synergistically to inhibit the growth and spread of renal cancer cells. In a multicenter, randomized study, the combination of lenvatinib and everolimus was evaluated in the treatment of advanced or metastatic renal cell carcinoma. The results showed that the combination of lenvatinib and everolimus could significantly extend the progression-free survival (PFS) and overall survival (OS) of patients compared with everolimus alone. Specifically, the median PFS in the combination group was 14.6 months, while the median PFS in the everolimus alone group was only 5.5 months. In addition, the combination group also showed a higher objective response rate (ORR), which means more patients had their tumors shrink or disappear after using the combination treatment.

In addition to its remarkable efficacy, the combination of everolimus and lenvatinib is relatively safe. Although both drugs may cause some adverse effects, such as stomatitis, infection, weakness, etc., these symptoms can usually be controlled with appropriate medical management. In addition, doctors will also adjust drug dosage and usage according to the patient's specific conditions to minimize the occurrence of adverse reactions.